Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2460-2472

  Zhao, Qi ^a   Caballero, Otavia L ^a   Davis, Ian D ^b,c   Jonasch, Eric ^d   Tamboli, Pheroze ^e   Yung, W K Alfred ^d   Weinstein, John N ^d   Shaw, Kenna ^d   Strausberg, Robert L ^a   Yao, Jun ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 4; CLAUDIN 7; CLAUDIN 8; CYTOKERATIN 7; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; TRANSCRIPTOME; UVOMORULIN; VIMENTIN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ESRP1 GENE; EXON; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIB ISOFORM GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 2 IIIC ISOFORM GENE; GENE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE SWITCHING; GENETIC ASSOCIATION; GENOMICS; GRHL1 GENE; HISTOPATHOLOGY; HOXA4 GENE; HOXB GENE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MESENCHYMOMA; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RNA SEQUENCE; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR VOLUME;

ALTERNATIVE SPLICING; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DNA METHYLATION; DNA-BINDING PROTEINS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; ORGAN SPECIFICITY; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RNA, MESSENGER; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84877099987     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3708     Document Type: Article

References (50)

1. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007;8:749-61. (Pubitemid 47429207)
2. Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011;7:e1002218.
3. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3. (Pubitemid 351380249)
4. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010;463:364-8.
5. Sveen A, Bakken AC, Agesen TH, Lind GE, Nesbakken A, Nordgard O, et al. The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer. Int J Cancer 2012;131:1479-85.
6. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-9.
7. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005.
8. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235-53.
9. Igarashi M, Finch PW, Aaronson SA. Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J Biol Chem 1998;273:13230-5. (Pubitemid 28246895)
10. Orr-Urtreger A, Givol D, Yayon A, Yarden Y, Lonai P. Developmental expression of two murine fibroblast growth factor receptors, flg and bek. Development 1991;113:1419-34.
11. Muh SJ, Hovhannisyan RH, Carstens RP. A non-sequence-specific double-stranded RNA structural element regulates splicing of two mutually exclusive exons of fibroblast growth factor receptor 2 (FGFR2). J Biol Chem 2002;277:50143-54. (Pubitemid 36014468)
12. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009;33:591-601.
13. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 1998;17:1642-55. (Pubitemid 28119118)
14. Jackson D, Bresnick J, Rosewell I, Crafton T, Poulsom R, Stamp G, et al. Fibroblast growth factor receptor signalling has a role in lobuloalveolar development of the mammary gland. J Cell Sci 1997;110:1261-8. (Pubitemid 27273696)
15. Dillon C, Spencer-Dene B, Dickson C. A crucial role for fibroblast growth factor signaling in embryonic mammary gland development. J Mammary Gland Biol Neoplasia 2004;9:207-15. (Pubitemid 39177504)
16. De Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I, Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 2000;127:483-92. (Pubitemid 30093396)
17. Revest JM, Suniara RK, Kerr K, Owen JJ, Dickson C. Development of the thymus requires signaling through the fibroblast growth factor receptor R2-IIIb. J Immunol 2001;167:1954-61. (Pubitemid 32747500)
18. Lin Y, Liu G, Zhang Y, Hu YP, Yu K, Lin C, et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 2007;134:723-34. (Pubitemid 46437914)
19. Lipschutz JH. Molecular development of the kidney: a review of the results of gene disruption studies. Am J Kidney Dis 1998;31:383-97. (Pubitemid 28124093)
20. Finch PW, Rubin JS. Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst 2006;98:812-24. (Pubitemid 43923439)
21. Terada M, Sakamoto H, Ohmura Y, Tsuruta H, Akiyama N, Sasaki H, et al. Biological significance of gene amplification in carcinogenesis. Princess Takamatsu Symp 1991;22:371-80.
22. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340-8. (Pubitemid 351521808)
23. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4. (Pubitemid 47014500)
24. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
25. Miki T, Fleming TP, Bottaro DP, Rubin JS, Ron D, Aaronson SA. Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 1991;251:72-5. (Pubitemid 21916854)
26. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62. (Pubitemid 350059681)
27. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008;33:233-7.
28. Diez de Medina SG, Chopin D, El Marjou A, Delouvee A, LaRochelle WJ, Hoznek A, et al. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997;14:323-30. (Pubitemid 27073087)
29. Feng S, Wang F, Matsubara A, Kan M, McKeehan WL. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Cancer Res 1997;57:5369-78. (Pubitemid 27516376)
30. Zhang Y, Wang H, Toratani S, Sato JD, Kan M, McKeehan WL, et al. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc Natl Acad Sci U S A 2001;98:11336-40. (Pubitemid 32928729)
31. Matsubara A, Kan M, Feng S, McKeehan WL. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998;58:1509-14. (Pubitemid 28193616)
32. Yoshino M, Ishiwata T, Watanabe M, Komine O, Shibuya T, Tokunaga A, et al. Keratinocyte growth factor receptor expression in normal colorectal epithelial cells and differentiated type of colorectal cancer. Oncol Rep 2005;13:247-52.
33. Zang XP, Pento JT. Keratinocyte growth factor-induced motility of breast cancer cells. Clin Exp Metastasis 2000;18:573-80. (Pubitemid 32964319)
34. Blanckaert VD, Hebbar M, Louchez MM, Vilain MO, Schelling ME, Peyrat JP. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res 1998;4:2939-47. (Pubitemid 29001465)
35. Ricol D, Cappellen D, El Marjou A, Gil-Diez-de-Medina S, Girault JM, Yoshida T, et al. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999;18:7234-43. (Pubitemid 30032102)
36. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997;15:3059-65. (Pubitemid 28043485)
37. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-22. (Pubitemid 23220358)
38. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M. Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 2001;46:163-72.
39. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, et al. Comparison of beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010;11:587.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
41. Bussolati B, Brossa A, Camussi G. Resident stem cells and renal carcinoma. Int J Nephrol 2011:286985.
42. Schmidt-Ott KM, Yang J, Chen X, Wang H, Paragas N, Mori K, et al. Novel regulators of kidney development from the tips of the ureteric bud. J Am Soc Nephrol 2005;16:1993-2002. (Pubitemid 41716430)
43. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010;102:428-35.
44. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005;11:5730-9. (Pubitemid 41170297)
45. Speicher MR, Schoell B, du Manoir S, Schrock E, Ried T, Cremer T, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994;145:356-64. (Pubitemid 24245836)
46. Gobbo S, Eble JN, Grignon DJ, Martignoni G, MacLennan GT, Shah RB, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol 2008;32:1239-45.
47. Bluemlein K, Gruning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget 2011;2:393-400.
48. Senga K, Mostov KE, Mitaka T, Miyajima A, Tanimizu N. Grainy-head-like 2 regulates epithelial morphogenesis by establishing functional tight junctions through the organization of a molecular network among claudin3, claudin4, and Rab25. Mol Biol Cell 2012;23:2845-55.
49. Cieply B, Riley Pt, Pifer PM, Widmeyer J, Addison JB, Ivanov AV, et al. Suppression of the epithelial-mesenchymal transition by grainyhead-like-2. Cancer Res 2012;72:2440-53.
50. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.